Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)

About VarmX

Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio

News & events

All news
  • News

VarmX announces reltodecacog alfa (Relto) as the adopted non-proprietary name for VMX-C001

Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...

  • Management TeamNews

VarmX recognised with two prestigious industry award nominations

Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year”...

All news